PALISADES-1NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 52 versions: 30 with changes below, 20 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 10 words
- Enrollment closed, study ongoing
- Study sites: 34 to 36
- Secondary endpoints: details revised at 14 of 22 entries
- Notable Eligibility criteria expanded, about 15 words
- Primary endpoints: details revised at 1 of 3 entries
- Trial sites expanded: 28 → 34 locations
- Secondary endpoints: details revised at 16 of 22 entries
- Minor Study sites: 26 to 28v50
- Minor Trial sites expanded: 21 → 26 locationsv49
- Minor Trial sites expanded: 18 → 21 locationsv48
- Notable Primary and study completion pushed from Oct 2027 to Feb 2030
- Eligibility criteria expanded, about 9 words
- Trial sites expanded: 14 → 18 locations
- Secondary endpoints: 24 to 22
Notable Phase: Phase 1 to Phase 1/2v46 Show 5 more changesShow less
- Enrollment target: 114 to 247
- Eligibility criteria expanded, about 27 words
- Primary endpoints: 2 to 3
- Secondary endpoints: 16 to 24
- Study arms: 2 to 3
- Minor Primary and study completion dates: May 2027 to Oct 2027v44
- Minor Site details revised at 1 of 14 sitesv43
- Notable Primary and study completion dates: Jul 2026 to May 2027v42
- Minor Study sites: 12 to 14v41
- Minor Study sites: 10 to 12v39
- Minor Study sites: 9 to 10v34
- Minor Site details revised at 1 of 9 sitesv33
- Notable Primary completion date: Jul 2025 to Jul 2026
- Study completion date: Jan 2027 to Jul 2026
- Notable Primary completion date: Apr 2024 to Jul 2025
- Study completion date: Jan 2041 to Jan 2027
- Minor Study sites: 8 to 9v30
- Minor Study sites: 6 to 8v26
Notable Eligibility criteria expanded, about 6 wordsv25 Show 6 more changesShow less
- Enrollment target: 80 to 114
- Study sites: 5 to 6
- Interventions: Cyclophosphamide (Drug), Fludarabine (Drug), KITE-363 (Biological) to Cyclophosphamide (Drug), Fludarabine (Drug), KITE-363 (Biological), KITE-753 (Biological)
- Study arms: 1 to 2
- Study description shortened, about 4 words
- Study title expanded, about 2 words
- Minor Study sites: 4 to 5v24
- Study Identification, Study Status, Study Descriptionv23
- Minor Study sites: 3 to 4v22
- Notable Eligibility criteria expanded, about 12 wordsv21
- Minor Site details revised at 1 of 3 sitesv16
- Minor Study sites: 2 to 3
- Primary completion date: Feb 2024 to Apr 2024
- Notable Primary completion date: Jan 2026 to Feb 2024v10
- Minor Study sites: 1 to 2v8
- Notable Eligibility criteria shortened, about 30 words
- Start date changed from estimate of Nov 2021 to Oct 27, 2021
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Oct 2021 to Nov 2021
- Study site revised
- Minor Study sites: 0 to 1v3
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (22)
Show 17 moreShow less
Arms and interventions
Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable. \[Recruitment completed for this arm\]
Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable. \[Recruitment open for frontline LBCL and r/r MCL for this arm\]
Participants with r/r large B-cell lymphoma who have received at least 2 prior lines of systemic therapy will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells /kg intravenously (IV).
Drugs: Cyclophosphamide, Fludarabine
Biologicals: KITE-363, KITE-753
Sites
36 sites in 6 countries
United States 21, Australia 6, Canada 5, Netherlands 2, Germany 1, United Kingdom 1